Company Overview

company overview

Phebra, an Australian owned manufacturer, is committed to providing skills development and employment opportunities in the fields of research and development and production of commercial products for both local and export markets.

Phebra is an equal opportunity employer of more than 70 people and supports the health of Australians by supplying over 60 medicines in critical therapeutic areas.

Together with manufacturing medicines, Phebra collaborates with hospitals in developing sought after treatment solutions. It partners with companies to bring critical medicines into Australia. Phebra also supplies and out-licences products globally across the Pacific region, Asia, Europe, Canada, South Americas and the Middle East.

At Phebra, we have a corporate commitment to environmental sustainability. As such, 'green' initiatives are in place.

Evolution of Phebra

history
  • 1993
  • 1998
  • 2000
  • 2007
  • 2013

1993Pharmalab, a privately owned pharmaceutical company, was founded as a distributor of specialty pharmaceutical products.
Forward to 1998...

(Move cursor to time point)

Manufacturing

Phebra offers a large range of sterile injectable pharmaceuticals manufactured in its facility in Sydney, Australia. The new sterile manufacturing plant at Lane Cove West was officially opened in March 2013.

This plant allows Phebra to significantly boost its research and development and production capacity, for the Australian and overseas markets. In addition to the sterile injectable pharmaceuticals, Phebra also manufactures active pharmaceutical ingredients at this site. Other dosage forms such as topical products (creams) and oral formulations (tablets, suspensions, lozenges) are formulated at this new site in our development laboratory and manufactured by appropriate specialist groups.

The plant's increased capacity means Phebra will manufacture an ever-growing range of critical medicines, including emergency injectables, antidotes and other small volume injections. Phebra will also be expanding its capability to conduct all-important development programs now and into the future.

In addition to manufacturing its own products for Australian and export markets, Phebra is also contracted by other pharmaceutical companies to develop and manufacture products on their behalf.

Phebra's facility is licensed by the Australian Therapeutic Goods Administration (TGA) and is compliant to Good Manufacturing Practices (GMP).

manufacturing View Photo Galleryclick

 

Partnering with Phebra

Phebra focuses on marketing specialty pharmaceutical products. Phebra has partnerships with distributors and agents in New Zealand, Asia, South and North America and Europe.
Our Business Development team collaborates with clients in developing treatment solutions. Phebra welcomes clients to make contact to discuss their ideas for formulation, registration and/or supply of new products. Clients may use Phebra as a resource for specialist development, formulation and manufacture of small volume or difficult products.

Phebra also reviews opportunities to partner with companies planning to introduce critical medicines into Australia and South-East Asia. As a fully integrated pharmaceutical company, Phebra offers manufacturing, regulatory, pharmacovigilance, medical information, sales, marketing and distribution services.

Our product development and regulatory teams can assist with concepts of design, packaging and product formulation.
 

In-licensing of Hospital Specialty Products

Phebra is actively licensing specialty pharmaceutical products to market and distribute in the Asia Pacific region. We have, and seek, successful partnerships with:

    • specialty pharmaceutical companies with no representation in the Asia Pacific region who are looking for a commercialisation partner;
    • multinational pharmaceutical companies that wish to divest proprietary products;
    • biotech companies with products in late-stage clinical development.


Our experienced Sales and Marketing team have a strong understanding of the local market to successfully drive commercialisation of new products.

Our business focus is hospital specialty pharmaceuticals particularly in therapeutic areas and drug classes of: 

    • anaesthesia
    • antidotes
    • anti-infectives
    • central nervous system
    • emergency cardiovascular
    • in vivo diagnostic dyes and agents
    • infusion solutions, intravenous additives and electrolyte replacement solutions
    • oncology
    • pain
    • respiratory
    • specialty pharmaceuticals
    • vitamins



Out-licensing of Phebra's Products
Phebra is interested in partnering with international companies who are interested in commercialising our product range. 
 
Companies with potential in-licensing or out-licensing inquiries are welcome to contact Phebra. For more information on how we might be able to collaborate, please email us for a confidential discussion at businessdevelopment@phebra.com. 

PartneringWithPhebra

Energy Efficiency Program

As an Australian pharmaceutical manufacturer, Phebra is committed to reducing its environmental impact. 
Phebra is committed to protecting and improving the environment. To dramatically reduce its carbon footprint, Phebra is implementing wide ranging and innovative energy efficiency initiatives.

The opening of the new Sydney sterile manufacturing plant provided opportunity to embed efficiency solutions from the outset, as part of the day to day manufacturing and operations at the plant. The new system will lay the foundation for sustainable manufacturing processes well into the future.

The Energy Efficiency program includes:

    • installation of LED lighting in car parks, offices and the warehouse, where it's expected to cut energy consumption by more than 70%
    • lighting sensor system to ensure use on demand
    • air conditioning systems expected to save 20%
    • solar panelling
    • water conservation audits to drive water saving
    • pneumatic audits to identify, monitor and rectify air leaks


It is estimated that these initiatives will result in Phebra saving 328 tonnes of carbon each year.